CoChat

M1 Muscarinic Agonists as Potential Disease‐Modifying Agents in Alzheimer's Disease: Rationale and Perspectives

FISHER, A., MICHAELSON, D.M., BRANDEIS, R., HARING, R., CHAPMAN, S., PITTEL, Z. · 2000 · Annals of the New York Academy of Sciences
Cited by 62

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

A bstract: A cholinergic hypofunction in Alzheimer's disease (AD) may lead to formation of β‐amyloids that might impair the coupling of M1 muscarinic ACh receptors (mAChRs) with G proteins. This disruption in coupling can lead to decreased signal transduction, to a reduction in levels of trophic amyloid precursor proteins (APPs), and to generation of more β‐amyloids that can also suppress ACh synthesis and release, aggravating further the cholinergic deficiency. These “vicious cycles,” a presynaptic and a postsynaptic one, may be inhibited, in principle, by M1 selective agonists. Such properties can be detected in the functionally selective M1 agonists from the AF series [e.g., project drugs, AF102B, AF150(S)]. These M1 agonists promote the nonamyloidogenic APP processing pathways and decrease tau protein phosphorylation. The effects on tau proteins suggest a link between M1 mAChR‐mediated signal transduction system(s) and the neuronal cytoskeleton via regulation of phosphorylation of tau microtubule‐associated protein. This may indicate a dual role for M1 agonists: as inhibitors of two “vicious cycles,” one induced by β‐amyloids, and the other due to overactivation of certain kinases (e.g., glycogen synthase kinase‐3, GSK‐3) or downregulation of phosphatases, respectively. Prolonged administration of AF150(S) in apolipoprotein E‐knockout mice restored cognitive impairments, cholinergic hypofunction, and tau hyperphosphorylation, and unveiled a high‐affinity binding site to M1 mAChRs. Except M1 agonists, there are no reports of compounds having such combined effects, for example, amelioration of cognition dysfunction and beneficial modulation of APPs together with tau phosphorylation. This unique property of M1 agonists to alter different aspects of AD pathogenesis could represent the most remarkable, yet unexplored, clinical value of such compounds.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1749-6632.2000.tb06941.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 62

Metadata

Authors
FISHER, A., MICHAELSON, D. M., BRANDEIS, R., HARING, R., CHAPMAN, S., & PITTEL, Z.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2000-12
Volume
920
Issue
1
Pages
315-320
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W2090237566
Cited by
62
References
2
FWCI
4.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: M1 Muscarinic Agonists as Potential Disease‐Modifying Agents in Alzheimer's Disease: Rationale and Perspectives. https://app.cochat.ai/papers/10.1111/j.1749-6632.2000.tb06941.x
The paper
FISHER, A., MICHAELSON, D. M., BRANDEIS, R., HARING, R., CHAPMAN, S., & PITTEL, Z. (2000). M1 Muscarinic Agonists as Potential Disease‐Modifying Agents in Alzheimer's Disease: Rationale and Perspectives. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2000.tb06941.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.